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Highlights 
• Despite differences in residual helicity BH3 peptides bind equally fast to 
MCL-1.  
• Differences in stabilities results from off-rates, altering complex lifetimes. 
• This difference arises from variation in interactions at MCL-1 binding 
interface. 	
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Abstract  1 
The BCL-2 family of proteins plays a central role in regulating cell survival and 
apoptosis. Disordered BH3-only proteins bind promiscuously to a number of different 
BCL-2 proteins, with binding affinities that vary by orders of magnitude.  Here we 
investigate the basis for these differences in affinity.  We show that eight different 
disordered BH3 proteins all bind to their BCL-2 partner (MCL-1) very rapidly, and that 
the differences in sequences result in different dissociation rates. Similarly, mutation of 
the binding surface of MCL-1 generally affects association kinetics in the same way for 
all BH3 peptides but has significantly different effects on the dissociation rates. 
Importantly, we infer that evolution of homologous, competing complexes has resulted in 
producing complexes with significantly different lifetimes. 																																																								
1 BCL-2 : B cell lymphoma-2 
MCL-1 : Myeloid cell leukemia 1 
A1: BCL-2-related gene A1 
BAK: BCL-2 antagonist killer 1 
BAX: BCL-2 associated X protein 
CD: Circular Dichroism 
wt: wild-type 
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Introduction 
The physiological process of cell death, or apoptosis, is a highly regulated 
process and the B cell lymphoma-2 (BCL-2) family of proteins are important molecular 
arbitrators of the process1, 2. To date, five anti-apoptotic (BCL-2, BCL-xl, BCL-w, Myeloid 
cell leukemia 1 (MCL-1) and BCL-2-related gene A1 (A1)) and at least two pro-apoptotic 
BCL-2 proteins (BCL-2 antagonist killer 1 (BAK) and BCL-2-associated X protein (BAX)) 
have been identified3, 4. A third group of ten pro-apoptotic proteins (termed BCL-2 
homology domain (BH3)-only) are thought to interact with both pro-apoptotic BAK and 
BAX and also the anti-apoptotic proteins5-7. The BH3-only proteins can be divided into 
two groups; Activators (BIM, BID and PUMA) and Sensitizers (NOXA A, NOXA B, BMF, 
BIK, BAD, HRK)8. Several models have been proposed to understand the role of these 
pro and anti-apoptotic BCL-2 proteins8. In all these models, differences in affinity 
between the anti-apoptotic proteins and the pro-apoptotic proteins are predicted to 
determine their mode of action. These BCL-2 family proteins have a homologous BH3 
domain, which is intrinsically disordered in isolation, but form a contiguous helical 
segment upon binding to its partner BCL-2 proteins9-13. This disordered nature is likely 
be the source of promiscuity as well as selective binding, thus increasing the diversity 
and flexibility of this intricate network.  
The sequence alignment of eight BH3 peptides calculated using Clustal 
Omega14, 15, shows that there are only two absolutely conserved residues, although they 
all fold to the same structure upon binding - the calculated RMSD values show that the 
complexes of PUMA, NOXA A, NOXA B, BIM, BID and BAX with MCL-1 have high 
structural homology (Fig.1 A and C). Previous studies have shown that BH3 peptides 
bind to anti-apoptotic MCL-1 with different affinities2, 16, 17.     
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Here, we compare the interaction of eight BH3 peptides with MCL-1, by using 
kinetic and thermodynamic analyses to understand the biophysical nature of these 
interactions. Our results show that the association rates are within the same order of 
magnitude but there are large differences in the dissociation rates. We further 
investigate two mutants of MCL-1 that have previously been shown to increase the 
association rate constant of the PUMA peptide and find similar results for all the BH3 
peptides investigated in this study18. Our results are in line with our previous hypothesis 
that the BH3 binding groove of MCL-1 opens up to allow binding of the BH3 peptides18. 
Interestingly, we see larger differences in dissociation rate constants but the effect on 
off-rates is different for different peptides. Hence, the affinity of BH3 peptides to MCL-1 
is controlled by dissociation rate, which is a result of differences in the specific 
interactions of the BH3 peptides at the MCL-1 binding interface. The results presented 
here provide insight into the underlying molecular basis for both the promiscuity and the 
selectivity afforded by these structurally homologous complexes of BH3 peptides with 
pro-survival MCL-1. 
Results 
Different sequences impart different degrees of disorder  
Circular dichroism (CD) spectra reveal that the BH3 peptides investigated are mainly 
disordered under our experimental conditions. However, the percentage helicities of the 
BH3 peptides calculated from MRE value at 222 nm19, ranges between approximately 9-
63% (Fig 1B). Percentage helicity for the BH3 peptides estimated from CD does not 
correlate with predicted percentage helicity from Agadir20-22, or the predicted percentage 
disorder from PONDR VSL223-30, ESpritz (X-Ray)31-35 and ANCHOR36, 37(Fig S1). 
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Differences in affinity is due to differences in koff 
We investigated the kinetic signatures of seven different peptides (BID, BIM, BMF, 
NOXA A, NOXA B, BAK, BAX) and compared it with previously published data for PUMA 
18 interacting with wild-type (wt) MCL-1 (Table 1). The association rate constants, kon, 
vary by only an order of magnitude for all the peptides investigated (Fig. 2A, Fig. 3A). On 
the other hand, the dissociation rate constants, koff, differ by approximately four orders of 
magnitude (Fig. 2B, Fig. 3B). The equilibrium dissociation constants, Kd, also differ by 
four-five orders of magnitude and reflect the pattern of koff (Fig. 3C).  
Kinetic effects of mutation of MCL-1 binding interface 
 To investigate the role of partner protein in the interaction we studied two MCL-1 
mutations (V234A and T247A) in the binding groove (Table 2). We had previously shown 
that these mutations, although they weaken binding, actually slightly increase the 
association rate constant (kon) of wild-type PUMA18. Similarly, all BH3 peptides (except 
BAX) in our experiments have somewhat enhanced association rates to the MCL-1 
mutants, with kon increased by up to 4-fold, compared to wt (Fig. 4, Fig. S2). However, 
the effect of mutation in the binding groove of MCL-1 on dissociation rates differs by up 
to ~40-fold for different BH3 peptides, with some seeing a faster and some slower off-
rates compared to wt MCL-1 (Fig.4).   
Discussion 
The Kd values calculated from the kinetics data are presented in Tables 1 and 2. The 
activator BH3 peptides (PUMA BID and BIM) all have sub-nM affinities. The sensitizers 
are known to display more specificity in their binding, so NOXA B, known to bind MCL-1 
specifically also has sub-nM affinity whereas NOXA A and, in particular, BMF, bind more 
weakly. As expected, the effector, pro-apoptotic peptides BAK and BAX bind less tightly 
than the activator proteins (Table 1). These data are more-or-less consistent with 
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previously reported affinities for BH3 proteins interacting with wt MCL-1; given the 
differences in experimental conditions 2, 16, 17.  
Due to the abundance of charged residues and their disordered nature, IDPs are 
susceptible to changes in ionic strength and solvent environments38, 39. Patterning of 
charges is also known to affect the overall conformational ensembles of IDPs27, 40, 41. As 
increased residual structure in free IDP has been seen to increase affinity of IDPs to 
partner proteins, we investigated whether there is a relationship between residual helicity 
of the peptides and our kinetic and thermodynamic data42, 43. As shown in 
Supplementary Fig. S3, although differences in sequence result in differences in residual 
helicity of the BH3 peptides, we see no correlation between residual helicity and kon, koff 
or Kd (Fig.S3). 
kon values observed for all the BH3 peptides are within the range of association 
kinetics reported for most IDP:protein interactions (~105 - 108 M-1s-1)44, 45. However, 
despite differences in sequences, all the BH3-only peptides bind to wt MCL-1 with a 
similar association rate (Note that the scale in Fig 3A is very different to that of Figs. 3B 
or 3C).  Since, the BH3 peptides have only 6% sequence identity, the estimated charges 
of the peptides are varied, and we see that the kon is related to the estimated charge on 
the peptide (Fig. S4). Note that our experiments were conducted in a buffer of ionic 
strength = 100mM. Previous studies of the PUMA : MCL-1 interaction (PUMA has an 
estimated charge of ~-3 in our experimental conditions) have shown that increasing ionic 
strength slows the association of PUMA46. The fold-change from an ionic strength of 0 to 
infinite ionic strength is some 20-fold (although this is also ion-type dependent)47.  
However, variations in the physiological range (100-200 mM) affect the association rate 
by only approximately 2-fold47.  Thus, these marginal differences in kon observed for the 
BH3 peptides binding to MCL-1 may simply be due largely to differences in the charges 
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of the peptides, as was seen for a similar comparative study of different IDP ligands 
binding to KIX48. 
However, we find that the dissociation rate constants (koff) of the BH3 peptides 
from MCL-1 differ by 4-orders of magnitude. The results clearly reveal that differences in 
affinity reflect differences in the rate at which BH3 peptides dissociate (Fig. 5). This 
behavior has been observed for other IDP systems where the effect of post-translational 
modification (phosphorylation in pKID/KIX) and conserved helix flanking prolines 
(conserved prolines in MLL/KIX and p53/MDM2) were investigated49, 50. The results from 
these papers and the results presented here, suggest that different characteristic of IDPs 
primarily allow modulation of lifetimes of the IDP/partner complexes. This behavior of 
stability in signaling proteins being controlled by dissociation rate has been previously 
proposed to be functionally relevant50-52. Perhaps being disordered allows IDPs involved 
in complex network and signaling pathways, such as BH3 proteins, to adapt their 
kinetics allowing them to bind/unbind to many target proteins with different kinetics; that 
is, allowing promiscuous binding. This may also be why disorder is conserved and 
abundant in proteins involved in cell signaling processes53-55.                                                                                                                                                                                                                              
A structural alignment of the available complex structures of BH3 peptides 
(PUMA, BID, BIM, NOXA A, NOXA B and BAX) with MCL-1 (Fig 1C) reveals a close 
structural homology of these complex structures, with RMSDs 1.2 - 3.5 Å (Fig 1C). All 
BH3 peptides bind to the same ‘BH3-binding’ groove in MCL-1 and only minor structural 
differences are observed in the structural alignment. Analysis of the contacts formed, 
however, show that each peptide binds MCL-1 using a different subset of binding 
residues, similar to that suggested for A156 (Fig. S5). Previous NMR chemical shift 
analysis indicated similar changes in MCL-1 conformation upon BH3 peptide binding, 
suggesting that MCL-1 accommodates each BH3 ligand in a similar manner11, 57. Our 
results for the two conservative MCL-1 interface mutants (V234A and T247A), show that 
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although the effect on association kinetics is the same for all the BH3 peptides (i.e. we 
see marginal increase in association rates compared to wt MCL-1), the effects on the 
affinity of the complex (and thus the off-rates) is very different. Mutating the residues of 
MCL-1 causes changes in affinity by affecting the dissociation rate constant. In some 
cases, the effect is marginal, but in others the affinity changes by orders of magnitude.  
Furthermore, while most complexes are destabilized by mutation of interface residues in 
MCL-1, in others affinity is increased by several orders of magnitude (Fig 4).  
Interestingly, although the loss in affinity (∆∆G) is correlated with the number of 
contacting residues in the peptide for the MCL-1 mutant V234A, there is no such 
correlation for the T247A mutant (Fig. S5, Table 2).  We infer that there may be small 
adjustments of the structure of the peptide when binding to a mutant MCL-1. Thus, the 
differences in affinity are regulated by differences in specific contacts with the BCL-2-like 
partner (in our case MCL-1).  
Concluding Remarks 
We find that varying the dissociation rates essentially controls the affinity of a BCL-2 
protein, MCL-1, with different BH3 peptides. These differences in affinity are largely due 
to different interactions formed at the MCL-1 binding interface once the complex 
structure matures. Evolution of these homologous and competing complexes has 
resulted in different stabilities by modulation of the off-rates of these complexes.  We 
infer that it is the lifetime of the complex that may be the most important biophysical 
property in a competing network, such as the BH3:BCL-2 system. 
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Material and Methods 
Biophysical buffer 
All biophysical experiments were carried out in 50mM sodium phosphate buffer (0.05% 
Tween20), pH 7.0.  
Protein expression and purification 
Wild-type MCL-1 and mutants thereof (Mus musculus, 152-308 residues, Uniprot 
P97287) were expressed as described previously.46 The harvested cells after expression 
were resuspended in 1*PBS 25mM Imidazole, pH 7.5 and sonicated. The sonicate was 
centrifuged and the supernatant incubated with Ni2+- agarose resin for 1 hour at 4ºC. 
The protein bound to the Ni2+- agarose resin was then eluted with 1*PBS 500mM 
Imidazole (pH 7.5-8) and 2mM ethylenediaminetetraacetic acid (EDTA) was added to 
the elution to prevent precipitation. The protein solution was then buffer exchanged to 
1*PBS 25mM Imidazole, pH 7.5 using a 5kDa molecular weight cut off spin column. 600 
units of thrombin was then added to the protein solution and left overnight at room 
temperature to cleave off the HisTag. Thrombin cleaved supernatant supplemented with 
2mM CaCl2 to sequester the EDTA, was incubated with Ni2+- agarose resin for 1 hour to 
remove uncleaved protein. Cleaved protein was loaded into 5mL HiTrapTM SP HP ion-
exchange pre-equilibrated with 10mM HEPES, pH 7.5, and eluted using 1M NaCl buffer 
gradient. The protein was then loaded into Superdex G75 gel filtration column to elute 
with the biophysical buffer, 50mM Sodium phosphate (0.05% Tween20) pH7.0. Eluted 
protein was confirmed to be MCL-1 after analysis by gel electrophoresis and mass 
spectroscopy and stored at 4ºC.  
PUMA peptide with 35 residues (Mus musculus, 127-161 residues, Uniprot Q99ML1) 
with M144A mutation was expressed as described previously.58 The purification was 
also carried out as described before except that after binding to the Ni2+ agarose resin, 
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the resin was washed with 20mM Tris pH7.0, 10 mM imidiazole buffer and cleaved with 
Factor Xa in 20mM Tris, 50mM NaCl, 5mM CaCl2, pH 8.0 buffer. The cleaved 
supernatant was then purified by ion-exchange using 10mM Tris, pH8 and a linear 
gradient of 1M NaCl was applied and the protein eluted at 12-17%. The peptide was 
then further purified using Superdex G30 gel filtration column and eluted with the 
biophysical buffer, 50mM Sodium phosphate (0.05% Tween20) pH7.0. PUMA peptides 
were then frozen using liquid N2, and stored at -80ºC. 
Peptides  
All BH3 peptides (Uniprot code: PUMA - Q99ML1, BID - P70444, BIM - O54918, BMF – 
Q91ZE9, NOXA A – Q9JM54, NOXA B – Q9JM54, BAK – Q16611, and BAX – Q07812; 
35 amino acids, labeled with TAMRA dye at the N-terminus) were purchased from 
Biomatik. Peptides were dissolved in the biophysical buffer as required and filtered using 
a 0.22 mm cutoff filter. The stock solutions of peptides were frozen using liquid N2 and 
stored at -80ºC. 
Estimated parameters for peptides and PDB complex structures 
Estimated peptide charges were calculated using pKa values of amino acids for model 
peptides59 and corrected for addition of TAMRA dye at the N-terminus.  Agadir % helicity 
predictions were made for pH 7.0, 25 ºC and 100mM ionic strength20-22. Percentage (%) 
disorder predictions were generated using the tools PONDR-VSL223-25, 28-30, ESpritz (X-
Ray - chosen as the peptides are only 35 residues long and most have X-ray structures 
of bound complex with their partners available in the PDB)31-35 and ANCHOR36, 37.  To 
create the contact map, contacting residues of BH3 peptides PUMA, NOXA A, NOXA B, 
BIM, BID and BAX with MCL-1 were plotted from PDB structures 2ROC, 2ROC, 2JM6, 
2PQK, 2KBW and 3PK1. Contacts between the peptides and MCL-1 were defined 
between all non-hydrogen atoms within 4Å. Structural alignment for PDB structures 
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(2ROC, 2ROD, 2JM6, 2PQK, 2KBW and 3PK1) were built using PyMOL and RMSD 
values reported for each. 
Concentration measurements 
The concentrations of purified protein, MCL-1 (wild-type and mutants) and PUMA 
peptide were measured by absorbance at 280nm and calculated using extinction 
coefficients 22157 M-1cm-1 46 and 7113 M-1cm-1 18 respectively. The extinction coefficients 
were previously determined using amino acid analysis. 
TAMRA labeled peptide concentrations were determined from absorbance at 555nm, 
using extinction coefficient 83000 M-1cm-1. The extinction coefficient was again 
calculated by amino acid analysis of multiple peptide samples. 
Circular Dichorism (CD) and residual helicity 
Samples were prepared at different concentrations using the biophysical buffer. CD 
spectra (190-260 nm) were recorded in a 2mm path-length cuvette at 25ºC using a 
ChiraScan CD spectrometer from Applied Photophysics. All spectra were buffer 
subtracted and estimate for percentage helicities were calculated using average mean 
ellipticity at 222nm using the methods described previously19.  
Kinetic measurements 
For all kinetic experiments, an excitation wavelength of 555nm was used and emission 
above 570nm was measured. 
Association kinetics experiments were performed using a SX18 or SX20 fluorescence 
stopped-flow spectrometer from Applied Photophysics with the temperature maintained 
at 25ºC. Experiments were performed with 10-fold or larger excess of the folded partner 
(wild-type and mutant MCL-1) over TAMRA labeled BH3 peptides. An average of 30-40 
traces were fitted to an equation describing a single exponential process to extract the 
observed rate (kobs) for each concentration of the partner protein. The dependence of 
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kobs on the concentration of the partner protein was fit to a straight line, and the gradient 
of the line used to determine the association rate constant (kon). Fluorescence 
polarization accessory was used to measure anisotropy change instead of fluorescence 
change where signal change was poor.  
Out-competition dissociation kinetics experiments at 25ºC were carried out using SX18 
and SX20 fluorescence stopped-flow spectrometer from Applied Photophysics for kobs > 
0.03s-1 or a Varian Cary Eclipse spectrophotometer for kobs < 0.03 s-1.  A pre-formed 
complex of the partner protein and the TAMRA labeled BH3 peptides was mixed with 
different concentrations of unlabeled PUMA peptide, used as a competitor in these 
experiments. A change in fluorescence upon dissociation of the TAMRA labeled 
peptides was monitored and fitted to a single exponential equation to determine the kobs. 
In some cases, the change in fluorescence signal upon dissociation of the TAMRA 
labeled peptides was very small to monitor, therefore a fluorescence polarization 
accessory was used to monitor the change in anisotropy instead.  As a large excess of 
the competitor was used the kobs represents the dissociation rate (koff).  
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Figure Legends 
Fig. 1. BH3 peptides have different sequences and intrinsic helicities but fold to the 
same structure. (A) Sequence alignments of eight BH3 peptides (PUMA, BID, BIM, BMF, 
NOXA A, NOXA B, BAK and BAX). For each BH3 peptides the sequences from Mus 
musculus were aligned using Clustal Omega. Absolutely conserved residues are 
indicated by *, residues where the character of the residue is conserved denoted by a 
period (.)  (B) Percentage residual helicity calculated from mean residual elipticity (MRE) 
data obtained from Circular Dichorism (CD), see Methods; is shown for the eight N-
terminally TAMRA labeled BH3 peptides. The peptides show different degrees of 
disorder with BAX being least helical and BMF the most helical. (C) Structural alignment 
of available bound structures of MCL-1 (grey cartoon) with different BH3 peptides 
(colored cartoon; PUMA - dark blue (Protein Data Bank (PDB) entry: 2ROC11, Mus 
musculus), NOXA A - red (PDB entry: 2ROD11, Mus musculus), NOXA B - light green 
(PDB entry: 2JM657, Mus musculus), BIM – purple (PDB entry: 2PQK60, Homo sapiens), 
BID- yellow (PDB entry: 2KBW61, Homo sapiens), and BAX- dark green (PDB entry: 
3PK162, Homo sapiens)], built using PyMol. RMSD values calculated from PyMOL for 
each structural alignment are reported alongside. 
 
 
Fig. 2. Kinetics data for interactions of BH3 peptides (PUMA, BID, BIM, BMF, NOXA A, 
NOXA B, BAX and BAK) with wild-type MCL-1. (A) Observed rate constants for BH3 
peptides associating with wild-type MCL-1 under pseudo-first-order conditions with MCL-
1 in excess. (B) Observed rate constants for dissociation of BH3 peptides from wild-type 
MCL-1 obtained by mixing with an excess of out-competing peptide. Colors of the data 
points represent each BH3 peptides as shown in the legend at the top of the Figure. 
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Data for kinetics of PUMA interacting with MCL-1 was obtained from Rogers et al. 
201418. Note: unlike other BH3 peptides investigated in this study PUMA is not labeled 
with TAMRA or any other extrinsic dye18. 
 
Fig. 3. Representation of kinetic and thermodynamic parameters. (A) Association rate 
constant (kon) (B) Dissociation rate constant (koff) and (C) Equilibrium dissociation 
constant (Kd) for BH3 peptides binding to wt MCL-1. Larger differences in koff than kon are 
observed (note differences in scale of y-axes). The differences in Kd reflect the 
difference in koff. Colors for BH3 peptides as shown at the top of the figure. Data for 
PUMA are taken from Rogers et al. 18. 
 
Fig. 4. Fold-change in thermodynamics and kinetic parameters for BH3 peptides binding 
to MCL-1 mutants (V234A, left column and T247A, right column). Top: Fold-change in 
association kinetics (kon). Although most BH3 peptides bind slightly faster to mutant 
MCL-1, changes in kon upon mutation of MCL-1 are <5-fold for all the BH3 peptides 
investigated. Middle: Fold-change in association kinetics (koff) (Note different scale 
compared to top row). Change in koff upon mutation of MCL-1 for all the BH3 peptides 
investigated are more significant and very different, with a maximum change of 40-fold. 
Bottom: Fold-change in Equilibrium constant (Kd). Changes in (Kd) upon mutation of 
MCL-1 for all the BH3 peptides investigated reflect changes in koff with maximum 
changes of ~40-fold. The color for BH3 peptides as shown at the top of the figure. Data 
for PUMA are taken from Rogers et al. 18. 
 
Fig. 5. Correlation between kinetic and thermodynamic parameters studied for all BH3 
peptides interacting with wild-type and mutants of MCL-1. A.) koff vs kon; no co-relation is 
observed between association (kon) and dissociation kinetics (koff).  B) Kd vs kon; no co-
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relation is observed between equilibrium constant (Kd) and association kinetics (kon). C) 
Kd vs koff; a clear co-relation is observed between equilibrium constant (Kd) and 
dissociation kinetics (koff).  Note that the plots shown are in log scale. 
 
 Tables  
Table 1.  Kinetic and thermodynamic parameters of wild-type MCL-1 interacting with different 
BH3 peptides 
Protein BH3 peptides 
kon (M-1s-1) 
(x 106) 
 
koff (s-1) 
(x 10-3) 
Kd (M) 
(x 10-9) 
 
wt MCL-1 
PUMA 7.9 ± 0.2 1.4 ± 0.03 0.18 ± 0.01 
BID 8.8 ± 0.2 3.0 ± 0.1 0.34 ± 0.01 
NOXA A 3.6 ± 0.1 37 ± 2 10 ± 0.5 
NOXA B 0.7 ± 0.1 0.13 ± 0.01 0.19 ± 0.03 
BMF 1.5 ± 0.1 240 ± 30 160 ± 20 
BIM 5.7 ± 0.4 0.14 ± 0.01 0.025 ± 0.002 
BAX 4.0 ± 0.1 87 ± 2 22 ± 0.8 
BAK 1.7 ± 0.03 2.4 ± 0.2 1.4 ± 0.1 
Kd is calculated from kinetic rate constants (Kd = koff /kon). Errors reported in kon and koff are 
errors from the linear fit of observed rate constants. 
Errors for Kd were propagated using standard equations. Data for PUMA was obtained from 
Rogers et al. 201418 
 
 
  
Table 2.  Kinetic and thermodynamic parameters of mutant forms of MCL-1 interacting with 
different BH3 peptides 
 
Protein BH3 peptides 
kon (M-1s-1) 
(x 106) 
koff (s-1) 
(x 10-3) 
Kd (M) 
(x 10-9) 
∆∆G 
(kcal.mol-1) 
 
V234A MCL-1 
PUMA 10.1 ± 0.05 16 ± 0.04 1.6 ± 0.01 1.3 ± 0.03 
BID 12.7 ± 0.6 13 ± 0.4 1.0 ± 0.06 0.64 ± 0.04 
NOXA A 4.2 ± 0.04 750 ± 30 179 ± 7 1.7 ± 0.04 
NOXA B 1.2 ± 0.04 0.37 ± 0.01 0.32 ± 0.02 0.31 ± 0.1 
BMF 1.8 ± 0.04 690 ± 10 383 ± 9 0.52 ± 0.08 
BIM 6.5 ± 0.3 2.6 ± 0.1 0.40 ± 0.02 1.6 ± 0.06 
BAX 4.0 ± 0.3 730 ± 60 183 ± 21 1.3 ± 0.07 
BAK 4.8 ± 0.1 0.18 ± 0.02 0.038 ± 0.004 -2.1 ± 0.08 
 PUMA 8.9 ± 0.6 5.3 ± 0.3 0.60 ± 0.05 0.71 ± 0.06 
 BID 13.6 ± 0.3 3.8 ± 0.4 0.28 ± 0.03 -0.11 ± 0.07 
 NOXA A 4.7 ± 0.1 67 ± 2 14.3 ± 0.5 0.21 ± 0.04 
MCL-1 
 NOXA B 1.4 ± 0.01 0.24 ± 0.01 0.17 ± 0.01 -0.07 ± 0.10 
T247A BMF 3.0 ± 0.03 580 ± 70 193 ± 21 0.11 ± 0.10 
 BIM 7.4 ± 0.5 0.084 ± 0.001 0.011 ± 0.0008 -0.49 ± 0.06 
 BAX 4.5 ± 0.3 23 ± 1 5.1 ± 0.4 -0.87 ± 0.05 
 BAK 7.1 ± 0.2 0.062 ± 0.001 0.008 ± 0.0002 -3.06 ± 0.04 
 
Kd is calculated from kinetic rate constants (Kd = koff /kon) and ∆∆G = RT ln (Kd mutant / Kd wt). 
Errors reported in kon and koff are errors from the linear fit of observed rate constants. 
Errors for Kd, ∆∆G were propagated using standard equations. Data for PUMA was obtained 
from Rogers et al. 201418. 	
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Supplementary Figures  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. S1. No correlation was observed between estimated helicity (%) calculated from CD 
experiments and predicted helicity (%) or predicted disorder (%) calculated from online 
tools. Left: Estimated helicity (%) calculated from CD1 vs predicted helicity (%) using 
Agadir2-4 (black). Right: Estimated helicity (%) calculated from CD1 vs predicted disorder 
(%) using online tools PONDR VSL25-12 (green), ESpritz (X-Ray)13-17 (red), and 
ANCHOR18, 19 (blue). 
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Fig. S2. Comparing association kinetics data for all BH3 peptides (PUMA – dark blue, 
BID – yellow, BIM – purple, BMF – black, NOXA A – red, NOXA B – light green, BAX – 
dark green and BAK – orange) interacting with wt and mutants of MCL-1. Observed rate 
constants for BH3 peptides associating with MCL-1 under pseudo-first-order conditions 
with MCL-1 in excess. Closed circles with dotted line fit represent data obtained for wild-
type MCL-1. Open circles represent data obtained for V234A MCL-1 and closed squares 
represent data for T247A MCL-1. Compared to wt, faster association kinetics is 
observed for all BH3 peptides interacting with mutants of MCL-1 except for BAX. Data 
for kinetics of PUMA interacting with MCL-1 was obtained from Rogers et al. 201420. 
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Fig. S3. No correlation observed between percentage (%) residual helicity and kinetic 
and thermodynamic parameters studied for all BH3 peptides interacting with wild-type 
and mutants of MCL-1. Left: kon vs % residual helicity; Centre: koff vs % residual helicity; 
Right: Kd vs % residual helicity.  
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Fig. S4. 
Rate constants for association between wt MCL-1 and BH3 peptides correlate with 
peptide charge. Left: kon vs estimated charge, the straight line fit includes data for all 
BH3 peptides; Right : kon vs estimated charge, the straight line fit includes data points for 
all BH3 peptides except BAK (shown in orange) which seems to be an outlier. The 
charge on each peptide was calculated using pKa values reported for each amino acid 
for model peptides and corrected for the addition of TAMRA dye at the N-terminus21. 
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Fig. S5. Contact map for interactions between six BH3 peptides and MCL1. The 
contacts with MCL-1 for PUMA (blue) was obtained using PDB structure 2ROC22, for 
NOXA A (red) 2ROD22, for NOXA B (light green) 2JM623, for BIM (purple) 2PQK24, for 
BID (yellow) 2KBW25 and for BAX (dark green) 3PK126.Contacts between BH3 peptide 
and MCL-1 was defined between any non-hydrogen atom within 4Å distance. Note that 
three of these are for Murine peptides and proteins (2ROC, 2ROD, 2JM6) and three for 
human complexes (2PQK, 2KBW, 3PK1). 
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